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Chronic kidney disease (CKD) is relatively common in 
patients hospitalized for acute coronary syndrome (ACS) 
and is among the most powerful predictors of adverse in-
hospital outcomes and long-term mortality.1,2 The estimated 
glomerular filtration rate (eGFR) is the clinical standard for 
the assessment of kidney function.3 The Cockcroft–Gault 
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Abstract
Aims: Renal dysfunction is a powerful predictor of adverse outcomes in patients hospitalized for acute coronary 
syndrome. Three new glomerular filtration rate (GFR) estimating equations recently emerged, based on serum creatinine 
(CKD-EPIcreat), serum cystatin C (CKD-EPIcyst) or a combination of both (CKD-EPIcreat/cyst), and they are currently 
recommended to confirm the presence of renal dysfunction. Our aim was to analyse the predictive value of these new 
estimated GFR (eGFR) equations regarding mid-term mortality in patients with acute coronary syndrome, and compare 
them with the traditional Modification of Diet in Renal Disease (MDRD-4) formula.
Methods and results: 801 patients admitted for acute coronary syndrome (age 67.3±13.3 years, 68.5% male) and 
followed for 23.6±9.8 months were included. For each equation, patient risk stratification was performed based on eGFR 
values: high-risk group (eGFR<60ml/min per 1.73m2) and low-risk group (eGFR⩾60ml/min per 1.73m2). The predictive 
performances of these equations were compared using area under each receiver operating characteristic curves (AUCs). 
Overall risk stratification improvement was assessed by the net reclassification improvement index. The incidence of the 
primary endpoint was 18.1%. The CKD-EPIcyst equation had the highest overall discriminate performance regarding mid-
term mortality (AUC 0.782±0.20) and outperformed all other equations (ρ<0.001 in all comparisons). When compared 
with the MDRD-4 formula, the CKD-EPIcyst equation accurately reclassified a significant percentage of patients into 
more appropriate risk categories (net reclassification improvement index of 11.9% (p=0.003)). The CKD-EPIcyst equation 
added prognostic power to the Global Registry of Acute Coronary Events (GRACE) score in the prediction of mid-term 
mortality.
Conclusion: The CKD-EPIcyst equation provides a novel and improved method for assessing the mid-term mortality 
risk in patients admitted for acute coronary syndrome, outperforming the most widely used formula (MDRD-4), and 
improving the predictive value of the GRACE score. These results reinforce the added value of cystatin C as a risk 
marker in these patients.
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equation, based on serum creatinine concentration, has 
been the traditional method of estimating GFR.4 Later, the 
abbreviated Modification of Diet in Renal Disease (MDRD-
4) formula5 proved to be more accurate in predicting risk in 
patients with myocardial infarction,6 and now is the recom-
mended equation for use in daily clinical practice.2
In recent years, cystatin C has received much attention 
as a potential alternative to serum creatinine for estimating 
kidney function. This low molecular weight basic protein 
exhibits favourable properties for a renal biomarker such as 
free filtration by the glomerulus with no reabsorption and, 
compared with creatinine, it is less influenced by age, gen-
der, diet or muscle mass.7,8 In previous studies, it has con-
sistently shown to be a better risk marker than creatinine.9 
However, the lack of cystatin C-based equations has lim-
ited its clinical use.
New equations for estimating GFR have been recently 
published by the Chronic Kidney Disease Epidemiology 
Collaboration.3 In 2009, a formula based on serum creati-
nine (CKD-EPIcreat)10 has emerged but its use in laborato-
ries is very limited.11 In 2012, an equation based on serum 
cystatin C (CKD-EPIcyst) and another combining serum cre-
atinine and cystatin C (CKD-EPIcreat/cyst) were presented.12 
These equations are currently recommended to confirm the 
presence of renal dysfunction.3 However, studies in the area 
of ACS are still scarce.
The aim of the present study was to analyse the value of 
these three new eGFR equations in the prediction of mid-
term all-cause mortality in patients admitted for ACS, and 
to compare them with the traditional MDRD-4 formula.
Methods
Study population
One thousand and forty patients were consecutively admit-
ted to the Acute Cardiac Care Unit of a tertiary referral hos-
pital with a diagnosis of ACS between June 2009 and May 
2012. Patients in whom baseline blood samples with creati-
nine and cystatin C were not available (n = 171), those who 
died during hospitalization (n = 61) or those lost to follow-
up (n = 7) were excluded. Overall, 801 patients were 
included in our analysis.
Study design
Using collected baseline data at the time of ACS diagnosis, 
we retrospectively assessed the eGFR using the 4-variable 
MDRD formula5 and three new equations published by 
Chronic Kidney Disease Epidemiology Collaboration: 
CKD-EPIcreat,10 CKD-EPIcyst12 and CKD-EPIcreat/cyst.12 All 
the equations incorporate kidney-filtration markers (serum 
creatinine, cystatin C or both), as well as age, sex, race 
(Black versus nonBlack), except for the CKD-EPIcyst equa-
tion, for which the data on race are not required.
Serum creatinine was measured by a single laboratory 
using a method standardized to isotope-dilution mass spec-
trometry (IDMS), and serum cystatin C was determined by 
an assay traceable to the International Federation of Clinical 
Chemistry.
For each equation, patient risk stratification was per-
formed based on the eGFR, and according to the estab-
lished cut-off that defines CKD.3 Patients with an eGFR 
below 60ml/min per 1.73m2 were included in the high-risk 
group; an eGFR equal to or greater than 60 ml/min per 
1.73m2 classified the patient as low risk.
All equations were evaluated for their overall discrimi-
native performance and a comparison between the best of 
these three equations and the traditional MDRD-4 formula 
was performed. The characteristics and outcome of patients 
reclassified by the new equation into different risk groups 
were analysed, and the overall risk stratification improve-
ment was estimated.
The predictive power of this new equation was com-
pared with the Global Registry of Acute Coronary Events 
(GRACE) score and other common risk markers of worse 
prognosis.
Study outcome and follow-up
The primary endpoint was post-discharge all-cause mortal-
ity. Patients assigned to this study were followed for 23.6 ± 
9.8 months following their hospital discharge. Follow-up 
data were obtained from clinical records from outpatient 
clinic, hospital ward and emergency department admission, 
and through phone calls for patients not followed at our 
hospital.
Statistical analysis
Statistical analysis was done using SPSS, v. 17.0.
We assessed the discriminative performance of each 
equation by calculating the area under each receiver operat-
ing characteristic curve (AUC) by the DeLong method. 
This parameter quantifies the ability of a specific formula 
to classify those having an event as high-risk patients and 
those not having an event as low-risk.
Then, to test the usefulness of the new equations in 
improving risk stratification compared with the MDRD-4 
formula, we analysed the characteristics and outcome of 
patients who were reclassified to a different risk group 
(from high-risk to low-risk group and vice versa) by the 
equation with the highest AUC. To assess the overall 
improvement in reclassification, we obtained the net reclas-
sification improvement index (NRI), calculated according 
to the method described by Pencina et al.13 A positive and 
significant NRI translates a net overall successful reclassi-
fication of subjects into more appropriate risk categories, 
for example, a patient who reaches the primary endpoint 
who is reclassified into higher risk group with the new 
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equation or a subject who does not reach the primary end-
point who is reclassified into a lower risk category with the 
new equation. The amount of overall reclassification is 
translated by the extent of the NRI.
Multivariate logistic regression analysis was performed 
to evaluate whether the highest-performing GFR formula 
could add prognostic power to the GRACE score.
Results
Baseline characteristics
Clinical characteristics of the patients are shown in 
Table 1.
Risk stratification of patients based on 
different eGFR equations
The mean values of eGFR as measured by the MDRD-4 
formula, CKD-EPIcreat, CKD-EPIcyst and CKD-EPIcreat/cyst 
equations were 77.4 ± 31.6, 73.9 ± 27.7, 83.7 ± 34.4 and 
79.6 ± 31.7 ml/min per 1.73m2 respectively.
The prevalence of patients classified as high-risk (e.g. 
eGFR < 60ml/min per 1.73m2) ranged between 27.3% (by 
the CKD-EPIcyst equation) and 30.6% (by the CKD-EPIcreat 
equation), as illustrated in Table 2.
Predictive value of each eGFR equation and 
comparison between them
During a mean follow-up of 23.6 ± 9.8 months, 18.1% of 
patients died (n = 145).
The rates of the primary endpoint per risk group deter-
mined by each equation are reported in Table 3. As expected, 
the risk of death from any cause was consistently higher in 
patients included in the high-risk group, regardless of the 
equation used. All equations predicted this endpoint (p < 
0.001). Despite a similar prevalence of patients classified 
as high-risk between equations, high-risk patients accord-
ing to the CKD-EPIcyst equation had slightly higher mortal-
ity rates compared with high-risk patients according to any 
of the other formulae.
The discriminatory power of each formula was assessed 
by calculating the AUC for the primary endpoint (Figure 1, 
Table 4). The CKD-EPIcyst equation showed the highest 
predictive value in regard to post-discharge mortality 
(AUC 0.782 ± 0.20, 95% confidence interval (CI) 
Table 1. Baseline characteristics.
Characteristic  
Age, years 67.3 ± 13.3
Male gender 68.5% (n = 549)
NonBlack race 100% (n = 801)
Type of myocardial infarction NSTE-ACS 55.2% (n=442); STEMI 40.8% (n=327); other 4.0% (n=32)
Arterial hypertension 74.8% (n = 599)
Diabetes mellitus 31.0% (n = 248)
Hypercholesterolaemia 63.9% (n = 512)
Smoking habits 34.5% (n = 276)
Previously known coronary disease 25.3% (n = 203)
Mean serum creatinine, μmol/l 109.0 ± 109.2 (IQR 68.8–105.3)
Mean serum cystatin C, mg/l 1.10 ± 0.80 (IQR 0.69–1.18)
Admission Killip–Kimball class > 1 20.0% (n = 160)
Coronary angiography 94.9% (n = 760)
Number of vessels with significant lesionsa 1.54 ± 0.96
Revascularization procedures 81.6% (n = 556)
GRACE score for in-hospital mortality 134.9 ± 50.6
GRACE score for six-month mortality 111.1 ± 41.2
aSignificant coronary lesion was defined as ⩾ 50% stenosis of a major epicardial coronary artery.
NSTE-ACS: non-ST elevation acute coronary syndrome; STEMI: ST-segment elevation myocardial infarction; other: patients with previously known 
left bundle branch block or ventricular pacemaker rhythm; IQR: interquartile range; GRACE: Global Registry of Acute Coronary Events
Table 2. Categorization of patients in high- and low-risk groups 
according to each eGFR equation.
eGFR equation High-risk group Low-risk group




MDRD formula 29.5% (n =236) 70.5% (n = 565)
CKD-EPIcreat 30.6% (n = 245) 69.4% (n = 556)
CKD-EPIcyst 27.3% (n = 219) 72.7% (n = 582)
CKD-EPIcreat/cyst 28.3% (n = 227) 71.7% (n = 574)
eGFR: estimated glomerular filtration rate; MDRD: Modification of Diet 
in Renal Disease; CKD-EPIcreat: Chronic Kidney Disease Epidemiology 
Collaboration equation based on serum creatinine; CKD-EPIcyst: CKD-
EPI equation based on cystatin C; CKD-EPIcreat/cyst: CKD-EPI equation 
based on combined creatinine and cystatin C
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0.743–0.821) and outperformed all other equations (p < 
0.001 in all comparisons).
Risk reclassification with the CKD-EPIcyst 
equation
When compared with the MDRD-4 formula, the CKD-
EPIcyst equation reclassified 13.1% of the patients: 5.5% to 
a higher-risk group and 7.6% to a lower-risk group.
Patients who were reclassified to a higher-risk group by 
the CKD-EPIcyst equation were more likely to be older 
(79.5 ± 7.7 vs. 62.5 ± 12.6 years, p < 0.001) and female 
(45.4% vs. 25.0%, p = 0.003) compared with patients who 
remained in the low-risk group. In contrast, the patients 
Table 3. Post-discharge mortality rate (primary endpoint) according to eGFR equation risk-group stratification.
eGFR equation High-risk group Low-risk group p
 (eGFR < 60ml/min per 1.73m2) (eGFR ⩾ 60ml/min per 1.73m2)  
MDRD formula 32.2% (n = 76) 12.2% (n = 69) <0.001
CKD-EPIcreat 32.7% (n = 80) 11.7% (n = 65) <0.001
CKD-EPIcyst 39.7% (n= 87) 10.0% (n = 58) <0.001
CKD-EPIcreat/cyst 37.0% (n = 84) 10.6% (n = 61) <0.001
eGFR: estimated glomerular filtration rate; MDRD: Modification of Diet in Renal Disease; CKD-EPIcreat: Chronic Kidney Disease Epidemiology Col-
laboration equation based on serum creatinine; CKD-EPIcyst: CKD-EPI equation based on cystatin C; CKD-EPIcreat/cyst: CKD-EPI equation based on 
combined creatinine and cystatin C
Figure 1. Receiver operating characteristic (ROC) curves for post-discharge mortality prediction by different glomerular filtration 
rate estimation equations.
Table 4. Discriminatory power of each formula assessed by the 
area under each receiver operating characteristic curve for the 
primary endpoint.
Equation AUC 95% CI p
MDRD-4 formula 0.679 0.628 – 0.730 <0.001
CKD-EPIcreat 0.707 0.660 – 0.754 <0.001
CKD-EPIcyst 0.782 0.743 – 0.821 <0.001
CKD-EPIcreat/cyst 0.759 0.718 – 0.801 <0.001
AUC: area under each receiver operating characteristic curve; CI: 
confidence interval; MDRD: Modification of Diet in Renal Disease; 
CKD-EPIcreat: Chronic Kidney Disease Epidemiology Collaboration equa-
tion based on serum creatinine; CKD-EPIcyst: CKD-EPI equation based 
on cystatin C; CKD-EPIcreat/cyst: CKD-EPI equation based on combined 
creatinine and cystatin C
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reclassified to a lower-risk group by the CKD-EPIcyst equa-
tion were much younger (70.3 ± 10.5 vs. 77.5 ± 8.8 years, p 
< 0.001) and more frequently male (54.1% vs. 39.4%, p = 
0.05) than those who were not reclassified.
Reclassification of patients from low-risk to high-risk 
group by the CKD-EPIcyst equation predicted a significantly 
higher risk of events. The mortality rate of these reclassi-
fied patients was similar to the mortality rate of the CKD-
EPIcyst high-risk group (45.5% vs. 38.3%, p = 0.386), and 
much higher than the mortality of non-reclassified low-risk 
patients (45.5% vs. 9.4%, p < 0.001). Conversely, reclassi-
fication of patients from high-risk to low-risk group pre-
dicted a lower risk of events. The mortality risk of these 
patients was similar to the CKD-EPIcyst low-risk group 
(14.8% vs. 9.4%, p = 0.187) and much lower than that of 
non-reclassified high-risk patients (14.8% vs. 38.3%, p < 
0.001).
Overall improvement in reclassification
Overall, the CKD-EPIcyst equation correctly reclassified 
11.9% of cases into risk strata that were more accurate rep-
resentations of observed mortality risks.
The net improvement estimate for those not reaching the 
primary endpoint – the difference between patients cor-
rectly reclassified as a low risk (n = 52) and patients incor-
rectly reclassified as high risk (n = 24) divided by the total 
number of patients who did not reach the primary endpoint 
(n = 656) – was 4.27%.
The net estimate for those reaching the primary endpoint 
– the difference between patients correctly reclassified as 
high risk (n = 20) and patients incorrectly reclassified as 
low risk (n = 9) divided by the total number of events (n = 
145) – was 7.59%.
The NRI index was then the sum of these two net 
estimates: 11.9% (95% CI 4.1–19.6%, p (2-sided) = 
0.003). Cross tabulation between the MDRD-4 formula 
and CKD-EPIcyst equation (according to the level of risk 
estimated by both), with respective NRI, is described in 
Table 5.
Comparison of the predictive value of the 
CKD-EPIcyst equation with that of other 
common risk markers used in clinical 
practice
Multivariate logistic regression analysis showed that the 
CKD-EPIcyst equation (odds ratio (OR) 0.977, 95% CI 
0.970–0.983, p < 0.001) added prognostic power to the 
GRACE score (OR 1.015, 95% CI 1.009–1.022, p < 0.001) 
in the prediction of mid-term all-cause mortality in patients 
admitted for ACS. Comparison of a combined model 
including CKD-EPIcyst equation/GRACE score with the 
GRACE score alone, through receiver operating character-
istic (ROC) curve analysis, revealed that the discriminative 
value of the former (AUC 0.803 ± 0.19, 95% CI 0.766–
0.841) was greater than that of the GRACE score alone 
(AUC 0.757 ± 0.21, 95% CI 0.716–0.798), confirming the 
additive prognostic utility of the CKD-EPIcyst equation.
A Cox regression analysis showed the following varia-
bles as independent predictors of mid-term all-cause mor-
tality in these patients: CKD-EPIcyst equation (hazard ratio 
(HR) 0.973, 95% CI 0.968–0.979, p < 0.001), age (HR 
1.035, 95% CI 1.014–1.056, p = 0.001) and left ventricular 
systolic function (HR 1.342, 95% CI 1.179–1.528, p < 
0.001), while gender, Killip class, maximum troponin I, 
haemoglobin level at discharge and number of diseased 
coronary arteries were not associated with the endpoint.
Discussion
In the present study, all new equations for GFR estimation 
showed good discriminative power in the prediction of 
post-discharge all-cause mortality in patients with ACS. 
However, the CKD-EPIcyst equation revealed the highest 
overall discriminative performance and outperformed the 
most widely used eGFR equation – the MDRD-4 formula. 
Compared with the MDRD-4 formula, the CKD-EPIcyst 
equation accurately reclassified a significant percentage of 
patients into more appropriate risk categories. Furthermore, 
the utility of the CKD-EPIcyst equation was revealed by the 
Table 5. Net reclassification improvement obtained by the CKD-EPIcyst equation compared with the MDRD formula.
MDRD formula NRI
 Low-risk group High-risk group  
Events
CKD-EPIcyst equation Low-risk group 49 9 7.58%
 High-risk group 20 67  
Non-events
CKD-EPIcyst equation Low-risk group 472 52 4.27%
 High-risk group 24 108  
MDRD: Modification of Diet in Renal Disease; NRI: net reclassification improvement index; CKD-EPIcyst: Chronic Kidney Disease Epidemiology Col-
laboration equation based on cystatin C
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fact that it could add predictive value to the mostly widely 
used prognostic score in these patients – the GRACE score. 
The use of the CKD-EPIcyst equation in daily routine in an 
Intensive Cardiac Care Unit requires the additional meas-
urement of cystatin C in blood tests and increases labora-
tory costs only slightly. It is readily obtained, even in 
smaller community hospitals, and easily calculated through 
computerized algorithms. Our study suggests that the rou-
tine implementation of this equation could improve risk 
stratification of patients with ACS and potentially lead to 
more appropriate treatment decisions.
The role of cystatin C as marker of renal 
function
The high performance of the CKD-EPIcyst equation, com-
pared with the MDRD-4 formula and other creatinine-
based equations, highlights the value of cystatin C as a 
biomarker.
In recent years, the interest in cystatin C has been grow-
ing. It exhibits favourable metabolic properties (as free fil-
tration in the glomerulus, complete reabsorption and 
catabolism in proximal tubule and lack of tubular secre-
tion), and so its serum concentration is mainly determined 
by the GFR.8 Also, it is little influenced by muscular mass, 
age, sex or race.14 Only few less common circumstances 
have been described to increase the production of cystatin 
C: liver disease,15 hyperthyroidism16,17 and high doses of 
corticosteroids.17,18 Therefore, it has been proposed as a 
more reliable marker of renal function than serum creati-
nine, in particular in the detection of ‘preclinical’ kidney 
dysfunction.8 However, the lack of cystatin C-based eGFR 
equations has limited its use in clinical practice.
Since the publication of the guidelines of the Chronic 
Kidney Disease Epidemiology Collaboration a set of stud-
ies testing these new formulas have shown that the CKD-
EPI equations based on cystatin C – alone or in combination 
with creatinine – provide a more precise and accurate esti-
mate of GFR than creatinine-based equations.19 This was 
also confirmed in studies involving children.20 Therefore, 
the use of cystatin C-based equations is currently recom-
mended as a confirmatory test for CKD, namely in patients 
with mild kidney dysfunction, muscle wasting or chronic 
illness.19
Given that cystatin C is considered a better marker of 
renal (dys)function, and renal (dys)function is a prognostic 
marker in patients admitted with ACS, this may help explain 
why the CKD-EPIcyst equation (followed by the CKD-
EPIcreat/cyst equation) had a better performance in risk strati-
fication in the present study compared with other formulas.
Cystatin C: more than a renal biomarker
The role of cystatin C has not been limited to detection and 
stratification of CKD. In recent years, it has also emerged 
as a potential marker of cardiovascular risk.8
Cystatin C is an endogenous inhibitor of cathepsins, 
which are cysteine proteases secreted by all nucleated 
cells.21 The dynamic balance between cathepsins and cysta-
tin C modulates the catabolism of proteins and different 
physiological pathways, as neutrophil chemotaxis and tis-
sue remodelling.21 The unbalance between these two mol-
ecules triggers a set of pathophysiological mechanisms 
– extracellular matrix degradation, endothelial activation, 
lipid accumulation in vascular wall – responsible for the 
genesis and the progression of diseases with a known 
inflammatory hub, such as atherosclerosis.21 Some studies 
had described a positive correlation between elevated cys-
tatin C concentrations and high-sensitivity C-reactive pro-
tein and fibrinogen.22 In this perspective, cystatin C might 
be a systemic sensitive marker of ongoing inflammatory 
process that is the leading pathological mechanism promot-
ing several diseases, such as cardiovascular diseases.21
Some clinical studies have confirmed this relationship 
between cystatin C and cardiovascular disease, indepen-
dently of renal function. Parikh et al. reported that high con-
centrations of cystatin C were independently associated with 
cardiovascular risk factors, such as age, body mass index, 
low high-density lipoprotein cholesterol, and smoking, even 
in individuals without CKD or microalbuminuria.23 In a 
study of Svensson-Färbom et al., including middle-age sub-
jects without a history of cardiovascular disease, cystatin C 
proved to be a better risk marker for cardiovascular morbid-
ity and mortality than creatinine-based GFR.24 This relation-
ship has been also demonstrated in elderly patients.25
The prognostic role of cystatin C has also been studied 
specifically in acute patients. Higher levels of plasma cys-
tatin C have been associated with adverse outcomes in 
patients with ACS.26–29 In a study by Acuña et al., involving 
203 hospitalized ACS patients, elevated cystatin C values 
predicted the development of cardiovascular complications 
(in-hospital heart failure, myocardial infarction and cardio-
vascular death), and this association was stronger than that 
of other widely used parameters for estimating renal func-
tion (creatinine or GFR) and was maintained even in the 
group with normal GFR.22 Also, in patients with heart fail-
ure, cystatin C and the two new cystatin C-based equations 
have shown better prognostic performance than creatinine-
only based equations.30,31
Therefore, the prognostic role of cystatin C in ACS 
patients may be related not only to a more precise measure-
ment of kidney function but also to an association with non-
renal factors such as inflammation and atherogenesis, 
further reinforcing the importance of use of cystatin 
C-based equations in risk stratification of these patients.
Cystatin C-based GFR equation and risk 
stratification
In the present study, the new CKD-EPIcyst equation outper-
formed the creatinine-based formulas in risk stratification 
of patients with an ACS.
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Recent studies have shown a better estimate of morbidity 
and mortality risk when using cystatin C-based equations 
compared with creatinine-based equations, in a variety of 
populations: general-population,32 patients with CKD32 or 
heart failure.30 However, information about the usefulness 
of these new formulas in patients with ACS is still scarce.
In a study by Abu-Assi et al., including patients with 
acute myocardial infarction, the CKD-EPIcyst and CKD-
EPIcreat/cyst equations were the most accurate for predicting 
in-hospital mortality, rather than the MDRD-4 and CKD-
EPIcreat equations.33
A hypothesis for the best performance of the CKD-
EPIcyst rather than creatinine-based equations in risk strati-
fication was the confounding effect of non-GFR 
determinants of serum creatinine (muscle mass, diet and 
physical activity). Serum creatinine levels are lower than 
expected for the level of GFR in patients who are in poor 
health and who are most likely to die. Non-GFR determi-
nants of cystatin C also exist (obesity, inflammation, diabe-
tes), though they enhance the association between cystatin 
C-based eGFR and the risk of death.32
GFR estimating equations based on 
creatinine concentration
A particular finding in our study is the performance of the 
two creatinine-based formulas: the CKD-EPIcreat equation 
included a slightly higher percentage of patients in the 
high-risk group compared with the MDRD-4 formula 
(30.6% vs. 29.5%). According to previous studies, involv-
ing the general population, the CKD-EPIcreat equation was 
less sensitive but more specific for detecting eGFR < 60 
ml/min per 1.73m2, leading to a lower prevalence of 
CKD.34 This shift of distribution toward higher eGFR by 
this equation was more evident in younger patients (< 65 
years) and females.11 Our study involves higher-risk 
patients with a higher mean age and a higher prevalence of 
males, which may explain the similar percentage of 
patients with a mean eGFR < 60 ml/min per 1.73m2. 
However, the CKD-EPIcreat equation still had a better pre-
dictive value compared with the MDRD-4 formula, 
according to the AUC. These results are similar to the 
study conducted by Morici et al., involving elderly patients 
(⩾ 75 years) with ACS.35
Limitations of study
The moderate size of our single-centre sample should be 
considered the main limitation of this research. Our 
results should be validated in larger cohorts of patients 
before routine clinical implementation of the CKD-EPIcyst 
equation.
It is also noteworthy that this study was conducted in an 
entirely Caucasian population, so our results cannot be 
extrapolated to mixed race populations.
Patients (n = 171) in whom baseline blood samples with 
cystatin C were not available were excluded. However, 
their baseline characteristics (sex, age, cardiovascular risk 
factors, mean serum creatinine at admission and Killip 
class) were similar to those of the study patients. Mid-term 
mortality was also similar between groups.
Furthermore, the creatinine and cystatin C values were 
collected at the time of ACS diagnosis and therefore they 
do not reflect a steady state.
Conclusion
The CKD-EPIcyst equation provides a novel, widely appli-
cable and apparently improved method for assessing the 
mid-term mortality risk in patients admitted to hospital 
with an ACS, compared with the creatinine-based eGFR 
equations. The new equation improved the predictive value 
of the GRACE score, reinforcing its potential value in daily 
clinical practice in an Intensive Cardiac Care Unite. These 
results further highlight the added value of cystatin C as a 
risk marker in these patients.
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